

**ELECTROCARDIOGRAMS (ECG):**

**ECG TOXIDROMES:** looking for signs of cardiac toxicity

<b>QT prolongation</b>	<ul style="list-style-type: none"> <li>Potassium efflux blockers</li> </ul>
<b>QRS prolongation</b>	<ul style="list-style-type: none"> <li>Sodium channel blockers</li> </ul>
<b>Other</b>	<ul style="list-style-type: none"> <li>Sodium-potassium ATPase blockers</li> <li>Calcium channel blockers</li> <li>Beta-adrenergic blockers</li> </ul>

**ECG TO HELP ...**

<b>DIAGNOSE</b>	<ul style="list-style-type: none"> <li>CNS depression &amp; QT prolongation → <i>Quetiapine? Citalopram? Antipsychotics?</i></li> <li>Opioid toxidrome with runs of torsades → <i>methadone?</i></li> <li>Oropharyngeal burns &amp; ECG showing evidence of hyperkalemia or hypocalcemia → <i>hydrofluoric acid ingestion?</i></li> </ul>
<b>PREDICT</b>	<ul style="list-style-type: none"> <li>If patient has overdosed on a TCA</li> <li>If QRS &gt; 0.1 sec → 30% likelihood developing sz</li> <li>If QRS &gt; 0.16 sec → 50% likelihood developing ventricular dysrhythmias</li> </ul>
<b>GUIDE MANAGEMENT</b>	<ul style="list-style-type: none"> <li>If QRS &gt; 0.1 sec                             <ul style="list-style-type: none"> <li>Give 2-3 amps of IV sodium bicarbonate</li> <li>Can repeat boluses every 3-5 minutes until QRS interval narrows or until serum pH reaches 7.55</li> </ul> </li> <li>If QT prolonged                             <ul style="list-style-type: none"> <li>Check lytes &amp; top up (K, Ca, Mg especially)</li> <li>Consider IV Mg<sup>2+</sup> if QT &gt; 500-550</li> <li>Fix cause</li> </ul> </li> </ul>

**ECG IN THE POISONED PATIENT:**

- Abnormal ECG is common in the poisoned patient (approx. 70%)
  - 62% rhythm abnormality
    - Sinus tachycardia (51%), sinus bradycardia (7%)
    - AV block (7%), non-sinus atrial tachycardia (3%)
    - Nodal bradycardia (3%)
  - 38% morphological abnormality
    - Abnormal QRS (35%), QRS widening (33%)
    - QT prolongation (33%), PR prolongation (12%)
    - ST elevation (9%), ST depression (25%)
    - T wave inversion (20%)

<b>PR INTERVAL PROLONGED</b>	<ul style="list-style-type: none"> <li>Toxins that ↓ interatrial or AV nodal conduction lead to AV dissociation or blocks</li> <li>↓ <b>conduction</b> = CCBs, BBs</li> <li>↑ <b>vagal tone</b> = cholinergics</li> <li>Both <b>vagal tone &amp; direct effects</b> = digoxin</li> </ul>
<b>QRS WIDENED</b>	<ul style="list-style-type: none"> <li>Results of blocking fast sodium channels</li> <li>Leads to ventricular dysrhythmias</li> <li>Cyclic ADs                             <ul style="list-style-type: none"> <li>Class 1A                                     <ul style="list-style-type: none"> <li>Disopyramide</li> <li>Quinidine</li> </ul> </li> <li>Class 1C                                     <ul style="list-style-type: none"> <li>Propafenone</li> </ul> </li> </ul> </li> <li>Venlafaxine                             <ul style="list-style-type: none"> <li>Procainamide</li> </ul> </li> <li>Citalopram</li> <li>Carbamazepine</li> <li>Diphenhydramine / dimenhydrinate                             <ul style="list-style-type: none"> <li>Propranolol</li> </ul> </li> <li>Cocaine                             <ul style="list-style-type: none"> <li>Verapamil/diltiazem</li> </ul> </li> <li>(Hydroxychloroquine)</li> </ul>
<b>ST SEGMENT CHANGES</b>	<ul style="list-style-type: none"> <li>Characterizes myocardial ischemia or MI</li> <li>Seen w/ toxins that cause <b>vasoconstriction/ischemia</b> <ul style="list-style-type: none"> <li>Cocaine, other α-agonists, ergots</li> </ul> </li> <li>Also seen following <b>severe hypotension or hypoxia</b></li> </ul>
<b>T WAVE PEAKED</b>	<ul style="list-style-type: none"> <li>Evidence of early hyperkalemia</li> <li>As hyperK<sup>+</sup> worsens (6.5-8 mEq/L) → "sine wave"                             <ul style="list-style-type: none"> <li>PR &amp; QRS interval prolong and QRS merges with T waves</li> </ul> </li> <li>Hyperkalemia can occur with <b>chronic use</b> <ul style="list-style-type: none"> <li>Spironolactone, ACEI/ARBs, K<sup>+</sup> supplements</li> </ul> </li> <li><b>Acute hyperkalemia</b> with digoxin                             <ul style="list-style-type: none"> <li>T wave changes uncommon</li> </ul> </li> </ul>

**ECG CONTINUED:**

<b>QT INTERVAL PROLONG</b>	<ul style="list-style-type: none"> <li>Typically prolongs with slower HR</li> <li>If sufficiently long, can lead to v tach, v fib or TdP</li> </ul>	
	<b>CAUSES</b>	<ul style="list-style-type: none"> <li>Congenital</li> <li>Na channel blockers</li> <li>K channel blockers</li> <li>Electrolyte disturbance (Ca, K esp.)</li> </ul>
<b>DRUG CAUSES</b>	<ul style="list-style-type: none"> <li>Antidysrhythmics</li> <li>Antifungals</li> <li>Antibiotics                             <ul style="list-style-type: none"> <li>Quinolones</li> <li>Macrolides</li> </ul> </li> <li>Antipsychotics                             <ul style="list-style-type: none"> <li>Risperidone</li> <li>Haloperidol</li> <li>Quetiapine</li> <li>Olanzapine</li> <li>Ziprasidone</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>Antidepressants                             <ul style="list-style-type: none"> <li>TCA's</li> <li>Citalopram</li> <li>Venlafaxine</li> </ul> </li> <li>Other                             <ul style="list-style-type: none"> <li>Methadone</li> <li>Cocaine</li> <li>Diphenhydramine</li> </ul> </li> </ul>

**HEMODYNAMIC ABNORMALITIES IN THE POISONED PATIENT:**

**HEART RATE:**

<b>BRADYCARDIA</b>	<ul style="list-style-type: none"> <li><u>CNS depression</u>: sedatives, opioids, clonidine</li> <li><u>↑ vagal tone</u>: digoxin, cholinergics</li> <li><u>Na channel activation</u>: aconitine</li> <li><b>Direct depressant effects on cardiac pacemakers</b>: beta blockers, calcium channel blockers</li> <li><u>Direct &amp; indirect</u>: metabolic acidosis, severe hyperK</li> </ul>
<b>TACHYCARDIA</b>	<ul style="list-style-type: none"> <li>Most common rhythm disturbance in poisoned pt</li> <li><u>Direct effect</u>:                             <ul style="list-style-type: none"> <li>Cocaine, sympathomimetics, anticholinergics, methylxanthines</li> <li>Agitation, withdrawal states</li> </ul> </li> <li><u>Indirect states</u>: secondary to                             <ul style="list-style-type: none"> <li>Hypotension, hypoxia, acidosis, fever</li> <li>Electrolyte disturbances, metabolic derangements</li> </ul> </li> </ul>

**BLOOD PRESSURE:**

<b>INCREASED</b>	<ul style="list-style-type: none"> <li><u>Direct α-adrenergic agonists</u>: epinephrine, NE</li> <li><u>Indirect acting</u>: cocaine, amphetamines, MAOIs</li> <li><u>Direct &amp; indirect</u>: dopamine, imidazoline decongestants, pseudoephedrine</li> <li><u>Not α adrenergic receptors</u>: nicotine, vasopressin</li> </ul>
<b>DECREASED</b>	<ul style="list-style-type: none"> <li><u>Commonly from volume depletion</u></li> <li><u>Substances that affect venous tone</u>: sedative / hypnotics, clonidine</li> <li><u>Co-existing states</u>: hypoxia, acidosis, volume depletion, dysrhythmias</li> </ul>

**PUTTING THIS ALL TOGETHER:** approach to management requires integration of

- Vital signs
- Electrocardiogram
- What else is going on in patient

**CYCLIC ANTIDEPRESSANTS:**

<b>MECHANISMS</b>	<ul style="list-style-type: none"> <li>Anticholinergic (coma, tachycardia)</li> <li>Antihistaminic (coma)</li> <li>Inhibits reuptake of NE &amp; 5-HT (sz, hypotension)</li> <li>α-adrenergic blockade (hypotension)</li> <li>Na channel blocker (prolonged QRS, asystole)</li> </ul>
<b>TOXICITY</b>	<ul style="list-style-type: none"> <li>Severe toxicity results in coma, seizures, hypotension, dysrhythmias and death</li> <li>Onset within 4-6 mins; can be 30 min</li> <li>Death usually within first several hours                             <ul style="list-style-type: none"> <li>First 6 hours most critical, then next 6 hours</li> </ul> </li> <li>Toxic dose: &gt; 5 mg/kg in child and adult                             <ul style="list-style-type: none"> <li>&gt; 1 g = life threatening in an adult</li> </ul> </li> </ul>

ANTIDEPRESSANTS (CONTINUED):	
TREATMENT	<ul style="list-style-type: none"> <li>GI decontamination               <ul style="list-style-type: none"> <li>Can use charcoal &gt; 2 hours post, if intubated</li> </ul> </li> <li>QRS widening (QRS &gt; 0.1 sec) and other conduction abnormalities               <ul style="list-style-type: none"> <li>IV sodium bicarbonate boluses (2-3 amps or 1-2 mEq/kg) → repeat boluses every 3-5 mins until QRS interval narrows or until pH 7.55</li> <li>IV sodium bicarbonate boluses &gt; infusions</li> <li>NaHCO<sub>3</sub> produces alkalemia → reduces ionization of TCA molecules and may reduce binding to sodium channels</li> <li>Monitor for hypokalemia and fluid overload</li> </ul> </li> <li>Ventricular dysrhythmias refractory to IV NaHCO<sub>3</sub>, lidocaine may be useful               <ul style="list-style-type: none"> <li>Competes with TCA for Na channel → fewer Na channels blocked, conduction improved</li> <li>NOTE: lidocaine lowers seizure threshold and should be used with <i>caution</i></li> </ul> </li> <li>Hypotension unresponsive to IV fluids               <ul style="list-style-type: none"> <li>IV sodium bicarbonate boluses</li> <li>If persists, use norepinephrine (likely more effective than dopamine)</li> </ul> </li> <li>IV lipid emulsion therapy can be considered in patients <i>refractory</i> to standard resuscitation measures</li> <li>Seizures &amp; agitation should be controlled with IV BDZ</li> <li>Seizures refractory to high-dose BDZ should be treated with propofol, barbiturates, general anesthesia or neuromuscular paralysis (with continuous dosing)</li> </ul>

HIGH-DOSE INSULIN GLUCOSE THERAPY:	
RATIONALE	<ul style="list-style-type: none"> <li>Healthy heart uses free fatty acids for energy</li> <li>Stressed heart relies on carbohydrates</li> <li>CCBs inhibit insulin release from pancreas which ↓ glucose being actively transported into heart</li> <li>Providing energy to heart so it can respond to all other therapies being given (pressors, etc)</li> <li>Also, insulin has inotropic effects</li> </ul>
DOSE	<ul style="list-style-type: none"> <li><b>Loading dose:</b> 1 U/kg regular insulin</li> <li><b>Infusion:</b> 1 U/kg/hr regular insulin along with 0.5 g/kg/hr <b>dextrose</b> (5 mL/kg/hr of D10W or 2 mL/kg/hr of D25W)</li> <li>Can titrate up to 10 U/kg/hr insulin PRN BP</li> </ul>
MONITOR	<ul style="list-style-type: none"> <li>K, glucose, BP</li> <li>NOTE: if develop hypoglycemia, ↑ dextrose               <ul style="list-style-type: none"> <li>Do not decrease insulin dose</li> <li>Not sliding scale monitoring</li> </ul> </li> </ul>

BETA BLOCKERS:	
	<ul style="list-style-type: none"> <li>Similar approach except may get some response from glucagon infusion → ↓ Ca extrusion from cell and ↑ intracellular Ca</li> <li>At toxic levels, ↑ automaticity → dysrhythmias</li> <li>Also, ↑ vagal tone → ↓ HR and blocks</li> <li><i>Chronic</i> digoxin toxicity more common than <i>acute OD</i> <ul style="list-style-type: none"> <li>Risk factors: elderly, AKI, drug interactions</li> </ul> </li> </ul>

CALCIUM CHANNEL BLOCKERS:	
MECHANISM	<ul style="list-style-type: none"> <li>Inhibit L-type calcium channels in myocardium and smooth muscle</li> <li>Also block Ca channels in pancreas → hyperglycemia</li> </ul>
CLASSES	<ul style="list-style-type: none"> <li>Non-dihydropyridines (verapamil, diltiazem)               <ul style="list-style-type: none"> <li>Inhibit SA and AV node</li> </ul> </li> <li>Dihydropyridines (amlodipine, felodipine)               <ul style="list-style-type: none"> <li>Peripheral vasodilators</li> <li><i>Lose selectivity in overdose</i></li> </ul> </li> </ul>
TOXICITY	<ul style="list-style-type: none"> <li>Extension of therapeutic effects               <ul style="list-style-type: none"> <li>Hypotension - most common &amp; life-threatening</li> <li>Bradycardia</li> <li>CNS effects are secondary to ↓ BP &amp; hypoxia</li> </ul> </li> <li>Toxicity determined by               <ul style="list-style-type: none"> <li>Formulation and dose</li> <li>Co-ingestions – especially BBs</li> <li>Co-morbidities – CHF, cardiac disease</li> <li>Age</li> </ul> </li> </ul>
TREATMENT	<ul style="list-style-type: none"> <li>GI decontamination</li> <li>Hypotension/bradycardia               <ul style="list-style-type: none"> <li>IV fluids</li> <li>Atropine</li> <li>Calcium boluses (3-4 boluses, infusion?)                   <ul style="list-style-type: none"> <li>10-20 mL of 10% Ca chloride</li> <li>30-60 mL of 10% Ca gluconate</li> </ul> </li> <li>Vasopressors – often multiple</li> <li>High-dose insulin glucose therapy</li> </ul> </li> </ul>
OTHER TREATMENTS	<ul style="list-style-type: none"> <li>Methylene blue               <ul style="list-style-type: none"> <li>Case reports for refractory vasodilator shock amlodipine overdose (↓ nitric oxide activity)</li> </ul> </li> <li>Fat emulsion               <ul style="list-style-type: none"> <li>Only if failing other therapies</li> <li>Case report evidence only; weak evidence</li> </ul> </li> <li>ECMO</li> <li>Intra-aortic balloon pump</li> </ul>

DIGOXIN:					
MECHANISM	<ul style="list-style-type: none"> <li>Inhibits NaK-ATPase resulting in               <ul style="list-style-type: none"> <li>↑ Na intracellularly, which disrupts Na gradient → ↓ Ca extrusion from cell and ↑ intracellular Ca</li> <li>↑ Ca → ↑ contractility &amp; automaticity</li> <li>At toxic levels, ↑ automaticity → dysrhythmias</li> </ul> </li> <li>Also, ↑ vagal tone → ↓ HR and blocks</li> <li><i>Chronic</i> digoxin toxicity more common than <i>acute OD</i> <ul style="list-style-type: none"> <li>Risk factors: elderly, AKI, drug interactions</li> </ul> </li> </ul>				
TOXICITY	<table border="1"> <tr> <th>CARDIAC</th> <td> <ul style="list-style-type: none"> <li>Bradycardia (usually severe)</li> <li>Heart block – all degrees</li> <li>Atrial or ventricular dysrhythmias</li> <li>Death is secondary to asystole</li> </ul> </td> </tr> <tr> <th>NON-CARDIAC</th> <td> <ul style="list-style-type: none"> <li>Visual disturbances</li> <li>GI disturbances</li> <li>Confusion, agitation, weakness</li> <li>Hyperkalemia (common)</li> <li>Hypokalemia may occur in chronic OD</li> </ul> </td> </tr> </table>	CARDIAC	<ul style="list-style-type: none"> <li>Bradycardia (usually severe)</li> <li>Heart block – all degrees</li> <li>Atrial or ventricular dysrhythmias</li> <li>Death is secondary to asystole</li> </ul>	NON-CARDIAC	<ul style="list-style-type: none"> <li>Visual disturbances</li> <li>GI disturbances</li> <li>Confusion, agitation, weakness</li> <li>Hyperkalemia (common)</li> <li>Hypokalemia may occur in chronic OD</li> </ul>
CARDIAC	<ul style="list-style-type: none"> <li>Bradycardia (usually severe)</li> <li>Heart block – all degrees</li> <li>Atrial or ventricular dysrhythmias</li> <li>Death is secondary to asystole</li> </ul>				
NON-CARDIAC	<ul style="list-style-type: none"> <li>Visual disturbances</li> <li>GI disturbances</li> <li>Confusion, agitation, weakness</li> <li>Hyperkalemia (common)</li> <li>Hypokalemia may occur in chronic OD</li> </ul>				
DIAGNOSIS	<ul style="list-style-type: none"> <li>History, ECG, lytes, renal function, digoxin level</li> </ul>				
TREATMENT	<ul style="list-style-type: none"> <li>GI decontamination if recent, acute overdose</li> <li>Digoxin-specific antibodies (DigiFab)</li> <li>Hyperkalemia responds to antidote</li> </ul>				
MONITOR	<ul style="list-style-type: none"> <li>ECG, clinical status, VS, potassium</li> <li>No digoxin level after give DigiFab</li> </ul>				
DIGIFAB INDICATIONS	<ul style="list-style-type: none"> <li>Any potential digoxin-related life-threatening dysrhythmia, including:               <ul style="list-style-type: none"> <li>Severe ventricular dysrhythmias (v tach, v fib)</li> <li>Progressive bradydysrhythmias (severe sinus bradycardia or 2<sup>nd</sup> – 3<sup>rd</sup> degree heart block not responsive to atropine)</li> </ul> </li> <li>Serum digoxin level &gt; 12.8 nmol/L measured &gt; 6 hrs post-ingestion in an <i>acute</i> ingestion</li> <li><i>Acute</i> ingestion of &gt; 10 mg in an adult (4 mg in child)</li> <li>Serum potassium &gt; 5.5 mmol/L in <i>acute</i> ingestion</li> </ul>				

HYDROXYCHLOROQUINE:							
OVERVIEW	<ul style="list-style-type: none"> <li>Highly toxic in overdose</li> <li>Rapid onset of hypotension, ventricular dysrhythmias, cardiac arrest</li> <li>Hypokalemia, seizures, and coma common</li> <li>Death possible within 1-3 hours</li> </ul>						
MOA OF TOXICITY	<table border="1"> <tr> <td>CVS</td> <td> <ul style="list-style-type: none"> <li>Dose-related sodium and potassium channel blocking properties</li> <li>Direct cardiodepressant effects</li> <li>Delays repolarization, slows conduction</li> </ul> </td> </tr> <tr> <td>HYPOK<sup>+</sup></td> <td> <ul style="list-style-type: none"> <li>Direct membrane effect</li> </ul> </td> </tr> <tr> <td>CNS</td> <td> <ul style="list-style-type: none"> <li>Direct sodium channel effect and hypoperfusion</li> </ul> </td> </tr> </table>	CVS	<ul style="list-style-type: none"> <li>Dose-related sodium and potassium channel blocking properties</li> <li>Direct cardiodepressant effects</li> <li>Delays repolarization, slows conduction</li> </ul>	HYPOK <sup>+</sup>	<ul style="list-style-type: none"> <li>Direct membrane effect</li> </ul>	CNS	<ul style="list-style-type: none"> <li>Direct sodium channel effect and hypoperfusion</li> </ul>
	CVS	<ul style="list-style-type: none"> <li>Dose-related sodium and potassium channel blocking properties</li> <li>Direct cardiodepressant effects</li> <li>Delays repolarization, slows conduction</li> </ul>					
	HYPOK <sup>+</sup>	<ul style="list-style-type: none"> <li>Direct membrane effect</li> </ul>					
CNS	<ul style="list-style-type: none"> <li>Direct sodium channel effect and hypoperfusion</li> </ul>						
TOXIC DOSE	<ul style="list-style-type: none"> <li>Therapeutic dose: 200 – 400 mg/day</li> <li>Death: 11 – 12 g (teens)</li> <li>Survival: 4, 12, 22 g after aggressive care</li> </ul>						
KINETICS	<ul style="list-style-type: none"> <li>Rapidly absorbed</li> <li>Peak 2 – 4.5 hours</li> <li>Highly tissue bound (large Vd)</li> <li>Distributional half-life: 15-30 hours</li> <li>Elimination half-life: 4-40 days`</li> </ul>						
INTRAVENOUS LIPID EMULSION (ILE)	<ul style="list-style-type: none"> <li>Consider for drug-induced cardiotoxicity <b>not</b> responding to standard measures</li> <li>Proposed mechanisms still not clear                             <ul style="list-style-type: none"> <li>Intracellular vs. intravascular vs. Membrane</li> </ul> </li> <li>Case reports of use with variety of toxins</li> <li>ADRs                             <ul style="list-style-type: none"> <li>Acute pancreatitis</li> <li>Analytical interferences</li> <li>May bind other resuscitative drugs`</li> </ul> </li> </ul>						
TAKE HOME POINTS	<ul style="list-style-type: none"> <li>Uncommon, clinicians often unfamiliar</li> <li>May have to rapidly manage simultaneous QTc and QRS prolongation</li> <li>Requires aggressive supportive care</li> </ul>						

**KEY POINTS:**

- ECG is one of investigative tools to:
  - Establish diagnosis
  - Predict toxicity
  - Guide management
- Drugs with varying indications can share common cardiac toxicology
- Approach to management and monitoring can be systematic

**SUMMARY:**

- Ingestion was propafenone and digoxin
  - Na channel blocker and Na-K ATPase blocker
- Treatment directed at
  - VS, ECG, clinical signs
- Often don't know history or have labs initially when to have begin txt
- ECG will help guide therapy and decision making
- Use ECG info along w/ everything else you have learned from tox module